DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more
DongKoo Bio&Pharma Co. Ltd (006620) - Total Liabilities
Latest total liabilities as of September 2025: ₩158.34 Billion KRW
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has total liabilities worth ₩158.34 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DongKoo Bio&Pharma Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DongKoo Bio&Pharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Srisawad Capital 1969 PCL
BK:SCAP
|
Thailand | ฿18.37 Billion |
|
Intellistake Technologies Corp.
F:E41
|
Germany | €3.59 Million |
|
Elixir Energy Ltd
AU:EXR
|
Australia | AU$639.52K |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
USA | $24.86 Billion |
|
UHT Unitech Co., Ltd.
TWO:6618
|
Taiwan | NT$72.66 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
USA | $238.96 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down DongKoo Bio&Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DongKoo Bio&Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual total liabilities of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩138.73 Billion | +72.00% |
| 2023-12-31 | ₩80.66 Billion | +15.30% |
| 2022-12-31 | ₩69.95 Billion | +27.97% |
| 2021-12-31 | ₩54.66 Billion | +9.98% |
| 2020-12-31 | ₩49.70 Billion | +5.58% |
| 2019-12-31 | ₩47.07 Billion | +46.28% |
| 2018-12-31 | ₩32.18 Billion | -14.97% |
| 2017-12-31 | ₩37.85 Billion | -12.52% |
| 2016-12-31 | ₩43.27 Billion | -25.69% |
| 2015-12-31 | ₩58.22 Billion | -- |